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Take home message (250 characters)  
Lung clearance index (LCI) is sensitive to assess lung disease progression in children with 
cystic fibrosis in clinical routine. An increased change in LCI should prompt further diagnostic 
intervention to determine the underlying pathological process. 
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While lung clearance index (LCI) is a sensitive marker of small airway disease in individuals 
with cystic fibrosis (CF), less is known about longitudinal changes in LCI during routine clinical 
surveillance. 
Objectives 
To describe the longitudinal course of LCI in children with CF during routine clinical 
surveillance and assess influencing factors. 
Methods   
Children with CF aged 3 - 18 years performed LCI measurements every three months as part 
of routine clinical care between 2011-2018. We recorded clinical data at every visit. We used 
a multilevel mixed-effect model to determine changes in LCI over time and identify clinical 
factors that influence LCI course. 
Measurements and Main Results 
We collected LCI from 1204 visits (3603 trials) in 78 participants, of which 907 visits had 
acceptable LCI data. The average unadjusted increase in LCI for the entire population was 
0.29 LCI units/year (95% CI 0.20 - 0.38). The increase in LCI was more pronounced in 
adolescence, with 0.41 units/year (95% CI 0.27 - 0.54). Colonization with either 
Pseudomonas aeruginosa or Aspergillus fumigatus, pulmonary exacerbations, CF-related 
diabetes, and bronchopulmonary aspergillosis were associated with a higher increase in LCI 
over time. Adjusting for clinical risk factors reduced the increase in LCI over time to 0.24 LCI 
units/year (95% CI 0.16 – 0.33). 
 
Conclusion 
LCI measured during routine clinical surveillance is associated with underlying disease 
progression in children with CF. An increased change in LCI over time should prompt further 













Lung disease in cystic fibrosis (CF) starts early in life with bacterial infection and pulmonary 
inflammation leading to structural abnormalities [1, 2]. Damage to the lung during sensitive 
periods of lung growth and development can influence the trajectory of lung disease [1-3]. 
Therefore, early and sensitive monitoring of lung disease progression is essential. 
Conventional surveillance strategies have several limitations. Lung function monitoring using 
conventional methods such as spirometry is less sensitive to assess small airway pathology 
[4, 5]. Computed tomography (CT) leads to radiation exposure [6], bronchoalveolar lavage 
(BAL) requires sedation, and the invasive nature of both measures should limit their 
application to exigent clinical problems. Therefore, the multiple breath washout (MBW) 
technique has gained increasing interest as a non-invasive and sensitive tool to detect early 
CF lung disease [4, 5].  
The lung clearance index (LCI) is a global measure of ventilation inhomogeneity from MBW 
that is sensitive to early, peripheral lung disease in children with CF [4, 5]. In healthy 
individuals, LCI ranges between 6 and 8, an increase in LCI above these limits indicates 
worsening lung function [7]. LCI correlates with the extent of structural disease [8-10] and 
pulmonary inflammation [11] and is responsive to interventions [12, 13] in children with CF. 
Together, these data suggest that LCI is an appropriate clinical surveillance outcome in 
young children with CF. 
However, before LCI can be used to guide clinical decisions, further knowledge into the 
longitudinal course of LCI during routine clinical surveillance is needed. To date, studies into 
longitudinal changes in LCI have rarely extended beyond twelve months [14, 15], were 
performed in research settings [16], or used equipment that is currently not available [17, 
18]. At the Bern University Children’s Hospital, MBW measurements have been part of the 3-
 
monthly routine clinical surveillance of pediatric participants with CF since 2011 using a 
commercially available MBW device. We have utilized this unique dataset of LCI 
measurements from early childhood to adolescence to 1) assess the longitudinal course of 
LCI in children with CF during routine clinical surveillance, 2) identify the clinical factors 
associated with changes in LCI over time, and 3) assess the different abilities of LCI and FEV1 







This study was a longitudinal, observational, single-center study in children with CF aged 
three to 18 years attending 3-monthly outpatient clinical surveillance visits at the Bern 
University Children’s Hospital between 01/01/2011 and 31/12/2018. Clinical data was 
assessed retrospectively by structured chart review. Written informed consent was obtained 
from participants and caregivers at study entry and the study was approved by the local 
ethics committee in Bern.  
 
Clinical data  
Clinical data were collected at 3-monthly outpatient visits conducted by a pediatric 
pulmonologist using a standardized questionnaire. At each visit, symptoms and treatment 
review of the past three months, clinical examination, microbiological sampling (throat swab 
or sputum), and lung function testing (MBW, spirometry) were performed. Pulmonary 
exacerbations were assessed at each visit and respiratory symptoms classified according to 
the modified Fuchs criteria [19] (see Online Supplement). The influence of pro-inflammatory 
pathogens (Pseudomonas aeruginosa (P. aeruginosa), Aspergillus fumigatus (Aspergillus), 
Staphylococcus aureus (S.aureus), Haemophilus influenzae (H. influenzae), Streptococcus 
pneumoniae (S. pneumoniae) [20]) on LCI was examined as an acute effect at every visit and 
by the overall colonization status over the entire study period. Colonization status was 
considered chronic if the pathogen was present in at least 50% of the samples and 
intermittent if present less than 50% but at least once. This approach takes into account 
varying lengths of study participation [21]. Further, we assessed the influence of new 
acquisition of a pathogen on the course of LCI. Severe exacerbations were defined if the 
 
modified Fuchs criteria were fulfilled with subsequent need for intravenous (i.v.) antibiotics 
and considered as number per year to avoid overestimation of this factor in participants with 
longer follow-up. CF-related diabetes was defined according to ISPAD Guidelines (online 
supplement) and assessed as acute effect by the time of clinical evidence [22]. Acute 
bronchopulmonary aspergillosis (ABPA) was defined as occurring at least once over the 
study period or never. For data analysis, only participants with at least three clinical visits 
and acceptable lung function data were included. A detailed summary of variable definition 
is available in the online supplement.   
 
Lung function 
Nitrogen MBW tests were performed using the Exhalyzer D MBW device (Eco Medics AG, 
Duernten, Switzerland) and Spiroware software with settings according to current consensus 
[23] (Supplemental). Testing was performed using a mouthpiece and dead space adjusted 
according to the participant's weight. As different software versions were used for data 
collection during the study period (3.1.3, 3.1.6, 3.2.1), MBW trials were reloaded into the 
latest Spiroware version 3.2.1 to ensure comparability. Quality control was performed 
according to current guidelines [23-26] and tests with at least two acceptable MBW trials 
were included in our analysis. Spirometry (Jaeger MasterScreen, CareFusion, Hochberg, 
Germany) was performed after MBW according to ATS/ERS guidelines [27-30]. Results for 
spirometry are expressed as z- score values calculated from the Global Lung Initiative 




We used a mixed-effects linear regression model to assess the mean rate of change in LCI 
and spirometry indices with age included as linear term. We included a participant-specific 
random intercept and random slope to account for between-participant variability, different 
observation periods for each participant, and unequal numbers of study visits [32]. The 
baseline model was adjusted for sex and BMI. We then adjusted the final model for 
predefined clinically most relevant covariates. Next, we assessed all potentially influencing 
covariates on LCI course first in a univariate analysis and second in the fully adjusted model. 
We distinguished between time-invariant characteristics (sex, pathogen colonization, severe 
exacerbations, ABPA) and time-varying characteristics that were visit-specific (acute 
pathogen sampling, acute exacerbations, CF-related diabetes, BMI). Time-invariant 
covariates were included as main effects and interaction terms with age to assess whether 
covariates were associated with a steeper slope in LCI over time.  Visit-specific covariates 
were included as main effects only to assess the absolute differences in LCI  associated with 
the presence of the characteristic at a given time point. Non-parametric summaries are 
presented for skewed data; for normally distributed characteristics parametric summaries 
are used. Statistical analyses were performed using Stata 16.0 (StataCorp 2019, College 
Station; TX). Figures were created using Stata 16.0 or Graph Pad Prism (Prism G 2018, La 






Seventy-eight children (44 female) with CF between three and 18 years of age were 
monitored clinically and had MBW measurements performed between January 2011 and 
December 2018. Overall, 3603 MBW trials were reloaded and quality controlled in Spiroware 
3.2.1 and 1375 (38%) trials were excluded due to quality or technical issues (Figure 1). 
Feasibility by age group is summarized in Table E1. In total, 907 visits from 71 participants 
satisfied the inclusion criteria of at least three visits per participant with acceptable MBW 
data and matched clinical data. Demographical characteristics are summarized in Table 1 
and E2.  
 
LCI course over time without adjustments for risk factors 
First, we studied the increase in LCI over time without adjusting for clinical risk factors. As 
shown in Figure 2, LCI increased with age (mean slope of 0.29 LCI units/year, 95% confidence 
interval (CI) 0.2 - 0.38; p < 0.001). LCI was stable during the preschool years (slope = -0.4 LCI 
units/year (95% CI -1.1 – 0.33)) and started to increase at school age (0.21 (0.07 – 0.35)). The 
highest increase in LCI was observed during adolescence (0.41 (0.27 – 0.54). There was a 
significant interaction between age and LCI slope (p-value for interaction = 0.02) (Table 2). 
The pattern of LCI slope was different between males and females (Figure 2). Females 
displayed an earlier and more consistent increase in LCI over time than males, whereas 
males had a rapid increase in LCI between the ages of 10 and 14 years. Over the entire 
period there was no difference in the unadjusted increase in LCI between females (0.5 LCI 
units/year, 95% CI 0.27 – 0.63) and males (0.42 LCI units/year, 95% CI 0.21 – 0.64; p-value for 




Covariates associated with an increase in LCI over the study period 
The influence of clinical covariates on LCI course was first assessed in a univariate analysis 
and then in the full adjusted model (Table 3). We found that colonization with any 
proinflammatory pathogen was associated with a steeper increase in LCI over time as 
indicated by the significant interaction with LCI slope (Table 3). Aspergillus colonization was 
individually associated with a steeper increase in LCI, with a higher LCI slope in those 
chronically colonized compared with never colonized (Table 3, Figure 3). There was also a 
trend towards a higher LCI slope in those with chronic P. aeruginosa colonization compared 
with never colonized, which was not statistically significant (Figure 3). For S.aureus and H. 
influenzae colonization we found no significant interaction with LCI slope. Further, new 
acquisition of Aspergillus or P. aeruginosa was associated with a steeper increase in LCI slope 
compared with before colonization (Supplemental Table E3). Severe exacerbations and 
experiencing ABPA during the study period were associated with a steeper increase in LCI 
over time. The increase in LCI over time was independent of baseline characteristics 
(baseline LCI, follow-up time, comorbidities, and medication use) (Supplemental Table E4). 
 
Covariates associated with acute changes in LCI 
We also assessed visit-specific covariates that could result in acute changes in LCI (Table 4). 
Acute exacerbations and clinical evidence of CF-related diabetes were associated with acute 
changes in LCI. A higher BMI was associated with a better (lower) LCI. Acute, visit-specific 
pathogen colonization (any proinflammatory pathogen, Aspergillus, P. aeruginosa S.aureus, 




Increase in LCI over time with adjustments for risk factors 
When adjusting our model for the predefined clinically most relevant covariates sex, BMI, 
PsA- and Aspergillus-colonization, CF-related diabetes, acute and severe exacerbations, the 
increase in LCI over time diminished from 0.29 (0.2 – 0.38) (Figure 2) to 0.24 (0.16 – 0.33) LCI 
units/year (Figure 4, Supplemental Table E5). The change in LCI over time in the fully 
adjusted model indicates that also in absence of risk factors (e.g. colonization with 
P.aeurginosa), LCI would still increase substantially over time.  
After adjustment for clinical risk factors, the pattern of change in LCI at different ages was 
comparable to the unadjusted model, however, the overall increase in LCI was less 
pronounced (Figure 4, Table 2). The steeper increase in LCI observed in females during 
adolescence was due to a combination of different prevalences of risk factors and different 
effect sizes of covariates between males and females (Supplemental Table E6). After 
adjusting for all covariates in the final model, the increase in LCI over time was similar 
between females and males (Figure 4).   
 
Lung function over time for spirometry indices 
For spirometry indices, FEV1 and FEF25-75, the pattern of lung function decline for the entire 
cohort was comparable to LCI (Figure E1).  The unadjusted decrease was found to be -0.09 
FEV1 z-score/year (95% CI -0.14; -0.05); -0.09 FEF25-75 z-scores /year (95% CI -0.14; -0.04) and 
-0.3 FVC z-scores/year (95% CI -0.07; 0.01) , with no differences in slope between preschool, 
school-age and adolescence (Table E7). 
 
The association of time-invariant risk factors for spirometry indices was less pronounced 
than for LCI (Table E8 and E9). For time-dependent risk factors, only acute pulmonary 
exacerbation was associated with the rate of change of all spirometry indices (Table E10). 
The decrease in lung function over time after adjusting for risk factors remained similar to 
the unadjusted model (FEV1: -0.08 z-score/year (95%CI -0.13;  -0.04); FEF25-75: -0.07 z-





We found that LCI measured during routine clinical surveillance increased over time in 
children with CF, even after adjusting for clinical risk factors. LCI starts to increase at school-
age followed by a steeper increase during adolescence. LCI course was primarily influenced 
by pulmonary exacerbations, pathogen colonization, CF-related diabetes, and ABPA.  
 
Comparison with literature 
We report an increase in LCI over time between 0.24 and 0.29 LCI units/year, depending on 
which risk factors were adjusted for in the model. Only few studies have assessed the course 
of LCI over 12 months or longer, and have reported increases between 0.18 and 0.61 LCI 
units/year [14-18]. However, comparability of absolute LCI values may be limited due to the 
different methodologies and study designs.  
In our cohort, LCI remained stable during the preschool years (3 – 5 years) and did not 
significantly increase until school age and adolescence. This is contrary to findings of 
Stanojevic et al., who reported an increase in LCI of 0.4 LCI units/year over a two-year 
follow-up of preschool children with CF aged 2.5 to 6 years [16]. The cause of these 
divergent findings is unclear but likely to be influenced by these differences: i) cohort 
characteristics: mostly newborn screened CF patients in the Stanojevic study vs mostly 
clinically diagnosed in our cohort and ii) study design differences: research setting with 
standardized enrolment and follow-up compared with a clinical surveillance setting with 
different periods of enrolment and follow-up. Further, one major difference in our study was 
that the clinicians in our centre were not blinded to LCI. Therefore, preschool children with 
elevated LCI might have received more intensive treatment at a period where lung disease is 
still modifiable.  
 
Interestingly, follow-up data of the Stanojevic cohort [33] revealed that LCI flattened during 
school-age years, which they hypothesized was due to intense periods of treatment during 
preschool years. Substantial therapeutic changes in the last few years with the availability of 
CFTR-modulators may be an additional explanation of the different LCI trajectories between 
these two cohorts. Our findings are similar to the reported increase in LCI of 0.18 LCI 
units/year from preschool to adolescence in patients with CF in the study of Davies et al. 
[18]. While there are methodological differences to our study, the cohort assessed is 
clinically the most comparable currently available. The different patterns of LCI increase 
between males and females during adolescence only observed in our study are most 
probably attributable to the different prevalence of risk factors between males and females.  
Associations between LCI and disease markers have mostly been reported in cross-sectional 
or short-term longitudinal studies. A range of clinical factors, such as pulmonary 
inflammation, infection, and exacerbations have been shown to influence LCI [8, 11, 13, 34, 
35]. We confirmed that these clinical variables also influence the long-term course of LCI. A 
novel finding was the strong association between Aspergillus colonization and increase in LCI 
independent of other risk factors and occurrence of ABPA. While associations between 
Aspergillus infection and clinical outcomes have been reported previously, the impact of 
Aspergillus infection, especially in absence of ABPA diagnosis, on lung disease progression is 
unclear [36-38]. Interestingly, detection of Aspergillus in BAL samples from children with CF 
was associated with progression of structural lung disease on chest CT over time [34]. We 
also found that colonization with any proinflammatory pathogen and new acquisition of P. 
aeruginosa was associated with an increased LCI slope [20]. The detrimental effect of 
pulmonary exacerbations on long-term lung function decline has been reported previously 
 
for spirometry [39]. In our study, we could show that severe and acute pulmonary 
exacerbations were associated with acute and long-term effects on LCI course [13].  
While spirometry indices FEV1 and FEF25-75 showed comparable patterns of lung function 
decline to LCI, the association with age was less pronounced. Except for acute exacerbations, 
none of the risk factors assessed were consistently associated with spirometry outcomes. 
While direct comparison between spirometry outcomes and LCI was not the objective of our 
study, our findings suggest that LCI is more sensitive to detect underlying clinical 
manifestations of lung disease in children with CF compared to spirometry [4, 17]. 
 
Strengths and limitations 
One of the main strengths of the present study is the use of a longitudinal dataset of 
routinely measured LCI in a clinical cohort of children with CF. Despite an increasing number 
of studies using LCI as an endpoint, data on the long-term course of LCI are still limited. We 
used a commercially available MBW device and analyzed all data in the currently available 
software version to obtain high-quality MBW data. We performed rigorous quality control 
according to latest guidelines [23, 24, 26]. This approach led to a relatively high exclusion 
rate of MBW tests (24%). While these numbers appear high for an experienced center in 
MBW testing, it is important to note that MBW testing at our center started in 2011 before 
current quality control standards were available. Further, feasibility was lowest at preschool 
age, which is not unexpected and comparable to other studies (Supplemental Table E1)[40]. 
Thus, we believe our dataset is representative of LCI in the clinical setting as it incorporates 
all challenges associated with the use of LCI measurements in routine testing: limited 
measuring time, the broad age range of participants with varying disease severities, staff 
with different levels of testing experience and varying intervals between measurements. The 
 
definition of pathogen colonization status and the sensitivity of different sampling methods 
likely influenced the interpretation of pathogen data in our study. However, there is no clear 
consensus on how to define colonization in the clinical setting and recent omics-based 
monitoring further questions our understanding of culture-based pathogen detection [41]. 
In general, one of the major limitations of observational studies is to disentangle the direct 
effects of exposure variables from potential cofounding characteristics of the participants. 
This issue could have been minimized with a healthy control population which was not 
available for our cohort.   
 
Clinical relevance 
We found that LCI increases over time in children with CF even in the absence of risk factors, 
indicating that LCI is sensitive to assess disease progression without overt clinical symptoms. 
A wide spectrum of different clinical factors, including microbiology, pulmonary, and 
endocrinological complications were associated with increasing LCI, which suggests that LCI 
is useful to monitor disease pathology in CF. An increased LCI in individual children with CF 
should prompt further diagnostic tests. Overall, our results highlight the clinical validity of 
LCI for several reasons: (i) known clinical risk factors of disease progression influenced LCI 
course over time, (ii) LCI increases also in absence of risk factors, and (iii) adjusting for risk 
factors minimized differences in LCI course between female and male participants. 
 
Outlook 
Two main questions remain to be addressed before LCI can be recommended for 
widespread clinical use: (i) is LCI responsive to detect and monitor treatment changes in 
clinical practice? and (ii) would LCI guided therapy improve outcomes in children with CF? To 
 
answer these questions, randomized trials of LCI guided therapies [42] where clinicians are 
blinded to LCI results are needed. To better interpret and understand changes in LCI from a 
pathophysiological point of view, prospective longitudinal studies that compare LCI results 
with structural and/or functional imaging methods [43, 44] and direct comparison of 
conventional lung function parameters are required. Future longitudinal studies in cohorts of 
participants diagnosed by newborn screening and/or receiving novel CFTR-modulating 
treatments are needed to define the impact of these substantial diagnostic and therapeutic 
changes on LCI course. 
 
Conclusions 
These novel data from longitudinal clinical measurements provide further evidence that LCI 
is a sensitive measure to assess lung disease progression over time. An increased change in 
LCI should prompt further diagnostic intervention to determine the underlying pathological 
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Figure 1: Flow chart of study population and MBW tests included. Multiple breath 
washout tests were considered acceptable if at least two trials passed quality control 
review. Percentages of accepted MBW trials are calculated as proportion of the total 
number of trials. Percentage of accepted visits are calculated as proportion of the 
total number of visits. Percentage of participants included are calculated as 
proportion of the total participants evaluated. Abbreviations: MBW: multiple breath 
washout. 
Figure 2: LCI increase over time without adjustments. The increase in LCI is shown 
over age and was found, on average, to be 0.29 LCI units/year (95% CI 0.2; 0.38). 
Increase in preschool age was -0.4 LCI units/year (95%CI -1.1;0.33), in school-age 
0.21 LCI units/year (95%CI 0.07; 0.35), in adolescence 0.41 LCI units/year (95%CI 
0.27; 0.54) (p-value for interaction 0.02), with a steeper increase in females during 
adolescence. On the y-axis, LCI raw values are given. Line represents mean LCI 
2.5% across all participants with available data at a given age. Shaded areas 
represent point-wise upper and lower 95% confidence intervals, the dotted line refers 
to an upper limit of normal for LCI of 8. Abbreviations: LCI: lung clearance index. CI: 
Confidence interval. 
Figure 3 and b: Effect of pathogen colonization on LCI increase over time. Change in 
LCI over time with the corresponding confidence interval is given for participant 
groups that were colonized with Aspergillus or P.aeruginosa; either never, 
intermittent (1x – < 50% of the samples/observation time) or chronic (=50% of the 
samples/observation time). For Aspergillus (a), the slopes of LCI were significantly 
different within colonization groups and compared to the overall increase without 
pathogen colonization (p-value for interaction 0.04). For P.aeruginosa (b) 
colonization, the slope of LCI was only significantly different compared to the overall 
increase but not within colonization groups (p-value for interaction 0.2). P-values 
 
given refer to the comparison for each group to the never colonized group. Slope 
coefficient and predicted LCI are derived from the fully adjusted model (Supplemental 
Table E5). Circles, squares, and triangles represent the mean, whiskers upper, and 
lower 95% confidence interval. Abbreviations: P.aeruginosa: Pseudomonas 
aeruginosa; Aspergillus: Aspergillus fumigatus. LCI u/year: Lung clearance index 
units per year. 
Figure 3 and b: Effect of pathogen colonization on LCI increase over time. Change in 
LCI over time with the corresponding confidence interval is given for participant 
groups that were colonized with Aspergillus or P.aeruginosa; either never, 
intermittent (1x – < 50% of the samples/observation time) or chronic (=50% of the 
samples/observation time). For Aspergillus (a), the slopes of LCI were significantly 
different within colonization groups and compared to the overall increase without 
pathogen colonization (p-value for interaction 0.04). For P.aeruginosa (b) 
colonization, the slope of LCI was only significantly different compared to the overall 
increase but not within colonization groups (p-value for interaction 0.2). P-values 
given refer to the comparison for each group to the never colonized group. Slope 
coefficient and predicted LCI are derived from the fully adjusted model (Supplemental 
Table E5). Circles, squares, and triangles represent the mean, whiskers upper, and 
lower 95% confidence interval. Abbreviations: P.aeruginosa: Pseudomonas 
aeruginosa; Aspergillus: Aspergillus fumigatus. LCI u/year: Lung clearance index 
units per year. 
Figure 4: LCI increase over time with adjustments for risk factors. In the absence of 
risk factors, the increase in LCI is shown over age and was found to be 0.24 LCI 
units/year (95% CI 0.16; 0.33). Increase in preschool age was -0.48 LCI units/year 
(95%CI -1.2;0.22), in school age 0.16 LCI units/year (95%CI 0.03; 0.29), in 
adolescence 0.35 LCI units/year (95%CI 0.22; 0.49) (p-value for interaction 0.01), 
 
with a similar pattern of increase between males and females. On the y-axis, LCI 
values are given derived from the fully adjusted model as described in the manuscript 
and Supplemental Table E5. Line represents the point-wise mean LCI 2.5% across 
all participants at a given age, shaded areas representing upper and lower 95% 
confidence intervals, the dotted line refers to an upper limit of normal for LCI of 8. 

















Table 1: Patient demographics at baseline 
Patients (n) 71 
Female: n (%) 44 (62) 
Age (years)* 8.2 (4; 15.21) 
Mutation status  
Class I-III  70 (99) 
Class IV-VI 1 (1) 
Pancreatic function  
Insufficient 66 (93) 
Sufficient 5 (7) 
Weight z-score -0.22 (-2.86; 1.76) 
Height z-score -0.1 (-3.3; 2.32) 
BMI z-score -0.01 (-1.85; 1.65)  
FEV1 z-score -1.1 (-4.3; 1.49) 
LCI 2.5% 9.36 (6.45; 15.7) 
FRC (L) 1.1 (0.55; 2.8) 
Demographic characteristics of included participants. Data are 
presented as median (range) or n (%). Definition of abbreviations: BMI = 
Body mass index, FEV1: forced expiratory volume in one second, LCI: 
Lung clearance index, FRC: Functional residual capacity. *Age range for 
inclusion in this study was 3-18 years, however, the youngest participant 
that could be included for further analysis was 4 years old.  
Table 2: Increase in LCI over time from preschool age to adolescence 
 




95% CI p-value † 
Slope‡ 
(LCI u/year) 
95% CI p-value † 
3 - 5 years (N= 17) -0.4 -1.1; 0.33  -0.48 -1.2;  0.22  
6 – 11 years (N= 42) 0.21 0.07; 0.35  0.16 0.03;  0.29  
12 – 18 years (N= 12) 0.41 0.27; 0.54 0.02 0.35 0.22; 0.49 0.01 
Increase in LCI over time by age groups when adjusting for baseline characteristics and for potential 
risk factors (see full adjusted model in Table E5). LCI did not change during preschool years and started 
to increase at school age with the steepest increase at adolescence. Abbreviations: LCI u/year: LCI units 
per year, CI: Confidence interval.  
*  The slope coefficient is derived from the baseline model adjusted for sex and body mass index using 
age as the time variable and an interaction term for age group. 
† P- value from the interaction of age group with LCI slope.  
‡ The slope coefficient is derived from the fully adjusted model (Supplemental Table E5) using age as the 
time variable and an interaction term for age group. 
A positive coefficient indicates a worsening LCI (higher LCI), whereas a negative coefficient indicates an 











Sex    
Males (N=27) 0.21 0.07; 0.34  
Females (N=44) 0.27 0.15; 0.36 0.56 
    




   
Intermittent (N=9) 0.21 0.06; 0.37  
Chronic (N=62) 0.24 0.15; 0.32 0.001 
    
Aspergillus colonization      
Never colonized (N=40) 0.15 0.03; 0.26  
Intermittent (N=26) 0.31 0.18; 0.43  
Chronic (N=5) 0.48 0.21; 0.73   0.04 
    
P. aeruginosa colonization    
Never colonized (N=31) 0.18 
 
0.04; 0.31  
Intermittent(N=29) 0.23 0.11; 0.35  
Chronic (N=11) 0.40 0.2; 0.6 0.2 
    
H. influenzae  colonization    
Never colonized (N=18) 0.41 0.25; 0.56  
Intermittend (N=50) 0.19 0.09; 0.28  
Chronic (N=3) 0.24 -0.17; 0.66 0.07 
    
S.aureus colonization     
Never colonized (N=5) 0.23 -0.08; 0.54  
Intermittend (N=17) 0.07 -0.10; 0.24  
Chronic (N=49) 0.29 0.19; 0.39 0.09 
    
Severe exacerbations (N/year)    
0 /year (N=36) 0.12 -0.01;  0.24  
≥1x/year (N=35) 0.34 0.23; 0.45 0.01 
    
No ABPA /study period (N=62) 0.20 0.11; 0.28  
ABPA / study period (N=9) 0.40 0.26; 0.54 0.01 
    
Influence of time-invariant clinical covariates on LCI course in the fully adjusted analysis. 
Definitions of abbreviations:  LCI u/year: Lung clearance index units per year; CI: Confidence 
interval; Aspergillus: Aspergillus fumigatus; P.aeruginosa: Pseudomonas aeruginosa; ABPA: 
acute bronchopulmonary aspergillosis. 
Covariates assessed are time-invariant and considered in the model as stated over the entire 
study period. The slope coefficients are derived from a multilevel mixed effects model 
adjusted for the main effects of final selected covariates (fully adjusted model summarized 
in Supplemental Table E5). 
* Slope represents the increase in LCI over time compared within the group characteristic.  
The 95% CI represents the comparison to zero increase in LCI for each subgroup separately.  
A positive coefficient indicates a worsening LCI (higher LCI), whereas a negative coefficient 
indicates an improving LCI (lower LCI). Values in bold are statistically different from 0 at p 
<0.05 significance level.  
† P- value is derived from the interaction within the group characteristic and LCI slope 
# Proinflammatory pathogens were considered S.aureus, P.aeruginosa, H.Influenzae, 
S.pneumoniae and Aspergillus 
 




 LCI units 95% CI 
Acute Exacerbations (N = 586/907) 0.64 0.45; 0.83 
CF-related diabetes (N=84/907)* 1.1 0.37; 1.75 
BMI z-score  -0.60 -0.84; -0.36 
Influence of visit specific clinical covariates on acute LCI changes in the fully adjusted 
analysis. Definitions of abbreviations: LCI: Lung clearance index; CI: Confidence interval; 
CF: cystic fibrosis; BMI: Body mass index. 
Coefficients represent the increase in LCI at a given timepoint compared to those without 
the characteristic (95% confidence interval) and are derived from a multilevel mixed 
effects model adjusted for the main effects of final selected covariates (fully adjusted 
model summarized in Supplemental Table E5).  A positive coefficient indicates a 
worsening LCI (higher LCI), whereas a negative coefficient indicates an improving LCI 
(lower LCI). Values in bold are statistically different from 0 at p <0.05 significance level.  
*6 patients developed diabetes during the study period, 2 patients had diabetes at study 
entry; in total contributing to 84 visits with diabetes. 
 
Longitudinal course of clinical lung clearance index in children with cystic fibrosis  
 
Bettina S. Frauchiger, Severin Binggeli, Sophie Yammine, Ben Spycher, Linn Krüger, Kathryn 
A. Ramsey, Philipp Latzin  
 




Lung function testing 
Nitrogen multiple breath washout (MBW) tests were performed using an unmodified 
Exhalyzer D Device (EcoMedics AG, Duernten, Switzerland) and associated software 
Spiroware with settings according to current consensus guidelines [1]. The main outcomes 
reported were the lung clearance index (LCI) and functional residual capacity (FRC) in liters. 
Testing was performed in an upright position using a mouthpiece and a nose clip to ensure a 
leak-free system. Dead-space was adjusted according to participant's weight. For 
participant’s under 35 kg we used the dead space reducer set 2 and for heavier participants 
set 3, as recommended by the manufacturer. As measurements were collected in a clinical 
outpatient setting, roughly twenty minutes were spent per test and a minimum of two trials 
was collected. As MBW measurements were initiated in 2011 in our clinic, different 
Spiroware software versions (3.1.3, 3.1.6, 3.2.1) were used due to manufacturer-dependent 
improved software releases over the study period. To ensure the comparability of the 
outcomes, every MBW trial was reloaded manually in the latest software version Spiroware 
3.2.1. Every trial was quality controlled by an experienced reviewer (BF) according to recent 
guidelines [1-3]. An MBW test was considered successful if at least two acceptable trials 
were available wherefrom the mean LCI and FRC were calculated for further analyses. 
Spirometry (Jaeger MasterScreen, CareFusion, Hochberg, German) was performed after 
MBW according to ATS/ERS guidelines with the primary outcome FEV1 in liters [4].  
 
Pulmonary exacerbation assessment 
To assess pulmonary exacerbation status at each visit, symptoms were classified by the 
treating physician according to the modified Fuchs criteria provided by the EuroCareCF 
working group [5]: increased cough, increased quantity or change in sputum color, increased 
malaise or fatigue, less physical performance, increased dyspnea or shortness of breath, 
decreased appetite, loss of weight (> -5 percentiles or > 10% weight loss compared to the 
last visit) and decrease in FEV1 percent predicted > 10% compared to the last visit. A 
pulmonary exacerbation was defined if at least two of the modified Fuchs criteria were 
present and were considered independent of treatment decision. Treatment was considered 
separately for mild pulmonary exacerbations treated with oral antibiotics and assessed as 
acute effects at every visit. Severe pulmonary exacerbations were defined if at least two of 
the modified Fuchs criteria were met along with the subsequent need for intravenous 
antibiotic therapy and hospitalization. Severe exacerbations were considered as number per 
year to avoid overestimation of this factor in participants with longer study participation. 
Microbiological sampling 
Microbiological review is performed at every visit either by throat swab or spontaneous 
sputum sampling. We assessed the influence of pro-inflammatory pathogens (Pseudomonas 
aeruginosa (P. aeruginosa), Aspergillus fumigatus (Aspergillus), Staphylococcus aureus 
(S.aureus), Haemophilus influenzae (H. influenzae), Streptococcus pneumoniae (S. 
pneumoniae) [6]) cumulative and for each pathogen separately. Influence of pathogens on 
LCI was considered as acute effect at every visit and summarized as colonization status over 
the entire study period. Colonization status was considered chronic if pathogen was present 
in at least 50% of the samples and intermittent if present less than 50% but at least once. 
This approach takes into account varying lengths of study participation [7]. Further, we 
assessed the influence of acquisition of a pathogen on the slope of LCI. Herefore, we 
compared the slope of LCI before a pathogen was present to the slope after the first positive 
sampling.  
Genotype classification 
Genotype was grouped according to mutation classes, class I-III mutations representing the 
most severe phenotypes, class IV-VI mutations representing the milder phenotypes [8].  
Other outcomes studied 
We studied the effect of prophylactic treatment regimens, such as hypertonic saline 
inhalation, dornase alfa use, and chronically inhaled antibiotics. Participants were 
considered to be on the beforementioned treatments if adherence to the medication was 
present in at least 50% of the visits attended. CF-related diabetes (CFRD) was defined 
according to ISPAD Clinical Practice Consensus Guidelines and considered to be present if 
criteria for CFRD were met; either with or without fasting hyperglycemia [9]. Acute 
bronchopulmonary aspergillosis (ABPA) was evaluated if suspected by the treating physician 
by clinical signs and following serological analysis according to current guidelines [10]. Being 
a rare outcome, for further analysis in this study ABPA was considered as a binary outcome if 
at least one episode over the whole study period was present or if never occurred. To assess 
the potential influence of diagnosis before and after newborn screening was introduced in 
Switzerland, we studied if the increase in LCI over time differed between groups. Further, we 
assessed the effect of pancreatic insufficiency, total observation time in the study, and the 
year of diagnosis on the increase in LCI over time.  
 
Statistical analysis 
We used a mixed-effects linear regression model to assess the mean rate of change in LCI 
with age, which was included as linear term. We included a participant-specific random 
intercept which allows variation of the response variable LCI on the participant level 
(patient). The random slope for age accounts for between patient variability and handles the 
different observation times for each participant with unequal numbers of study visits [11]. 
Unstructured covariance was used to allow for different variance and covariance and 
correlation between slope and intercept; in other words, if LCI is correlated with the 
influencing variables.  Our baseline model was adjusted for sex and BMI z-score. Sex was 
chosen due to different lung development pattern for females and males [12-14]. BMI- z-
score was chosen as LCI is reported not to be independent of body size [15]. Using 
interaction terms, we tested for differences in LCI changes during adolescence (12-18 years) 
compared to school age (6-11 years) and preschool (3-5 years). To avoid variable selection 
only due to random fluctuation in the data [16], we predefined clinically deemed most 
relevant variables for the full adjusted model. The variables included in the final model were 
CF-related diabetes, acute pulmonary exacerbations, severe exacerbations, P.aeruginosa and 
Aspergillus colonization, and ABPA. Clinical covariates possibly influencing LCI course were 
first assessed in univariate analysis in the baseline model and then in the full adjusted 
model. We distinguished between time-invariant characteristics (sex, pathogen colonization, 
severe exacerbations, ABPA, medication, baseline characteristics) and time-varying 
characteristics that were visit-specific (acute exacerbations, CF-related diabetes, BMI, acute 
pathogen sampling). Time-invariant variables were included as main effects and in 
interaction terms with age. The latter allowed us to assess whether these variables were 
associated with trends in LCI (slope coefficient of age) over the whole study period.  For visit-
specific covariates, we included only main effects, allowing us to assess acute changes in LCI 
associated with the presence of the characteristic at a given time point. Statistical analyses 
were performed using Stata 16.0 (StataCorp 2019) [17] and graphs created using either Stata 




Median age at enrollment was 8.7 years (range 4 - 15.2 years). Average time of study 
participation was 5 years (range 0.4 - 7.1 years), with similar distribution across all age 
groups (Table E1). Participants excluded (N=7) for this study were significantly younger 
(Table E10), however, for most of these participants, the first visit performing an MBW was 
assessed without any training possibility before. Most patients (89%) were diagnosed before 
newborn screening was introduced in Switzerland in 2011, median age at diagnosis was 3 
months (range 0 - 124 months). Except for one participant, all patients were carriers of two 
disease-causing mutations (class I-III). 
Covariates associated with an increase in LCI over time 
The main predictors of LCI are discussed in the main article. All variables that were not 
significantly associated with an increased rate of change in LCI are summarized in 
supplemental table E4.  
Baseline characteristics 
We found no association for baseline characteristics (mutation class, pancreatic 
insufficiency, and diagnosis by newborn screening) with an increase in LCI over time. 
Further, we found no long-term effect on LCI of preventive inhalation with hypertonic saline 
and dornase alfa but for an intensified treatment regimen by prescribing inhaled antibiotics 
(Table E4). These patients had a steeper slope of LCI, indicating that prescribing inhaled 
antibiotics is most probably a marker of disease severity.  
At study entry, 93% of the patients were pancreatic insufficient and 89% of the children 
were diagnosed before newborn screening was introduced in Switzerland. For both 
covariates, the unequal sample sizes are most probably the reason why we found little 
evidence for an association with an increase in LCI.  Follow-up time was not associated with 
an elevated LCI either, ensuring that our results are not influenced by the length of 
observation time.  
Pathogen colonization 
The cumulative effect of colonization with any proinflammatory pathogen is presented in 
table 3. All patients were at least intermittent colonized with any proinflammatory pathogen 
(N=9) and the vast majority was colonized chronically with proinflammatory pathogens 
(N=62). Both, intermittent and chronic colonization with proinflammatory pathogens was 
associated with an increased slope of LCI. Aspergillus colonization was individually 
associated with a steeper increase in LCI, with a higher LCI slope in those chronically 
colonized compared with never colonized (Table 3, Figure 3). There was also a trend towards 
a higher LCI slope in those with chronic P. aeruginosa colonization compared with never 
colonized, which was not statistically significant (Figure 3). For S.aureus and H. influenzae 
colonization we found no significant interaction with LCI slope. 
This association of pathogen colonization and LCI increase over the whole study period was 
further confirmed by the finding that acquiring these pathogens (Aspergillus; P. aeruginosa) 
was associated with a subsequent increase in LCI by the time of clinical evidence 
(Supplemental Table E3). For acute infection with any proinflammatory pathogen, we could 
not find an association with acute changes in LCI. 
 
Influence of sampling method 
In total, 678 throat swabs and 213 sputum samples were available. Further, participants 
producing sputum were significantly older with a mean age of 13.0 compared to 11.2 
(p<0.001). Introducing the sampling type as a confounder in the model did not change the 
slope for age (0.24 LCI units/year). Sensitivity analysis by introducing sampling method as 
confounder revealed no influence on pathogen colonization and the slope of LCI when 




Table E1: Feasibility of clinical LCI and follow-up times by age groups 












3 - 5 years (N= 25) 125 64 51 2.7 (1.5; 5.9) 10 (3; 18) 
6 – 11 years (N= 42) 530 408 77 4.8 (0.4; 7.1) 14 (3; 27) 
12 – 18 years (N= 11) 546 442 81 4.5 (2.7; 6.2) 15 (4; 22) 
Summary of LCI feasibility after retrospective quality control and follow-up time in this study by age 
group. Data are presented as median and range or numbers and percentages. Age group refers to the 
age at study entry (only their initial visit was considered for this summary). Years of study 
participation and number of study visits refer to the total time participated in the study. 
 
 
Table E2: Patient demographics for excluded patients  
 
    Excluded Included p-value 
Patients (n) 7 71  
Female: n (%) 4 (57) 44 (62)  
Age (years) 4.3 (3.8 11.75) 8.2 (4; 15.21) 0.01 
Mutation status    
Class I-III  7 (100)) 70 (99)  
Class IV-VI  1 (1)  
Pancreatic function    
Insufficient 5 (71) 66 (93)  
Sufficient 2 (19) 5 (7)  
Weight z-score -0.12 (-1.66; 1.05) -0.22 (-2.86; 1.76) 0.61 
Height z-score 0.17 (-0.8; 0.9) -0.1 (-3.3; 2.32) 0.47 
BMI z-score 0.01 (-2.1; 1.03)  -0.01 (-1.85; 1.65)  0.80 
FEV1 z-score -0.8 (-4.3; 1.49) -1.1 (-4.3; 1.49) 0.97 
LCI 2.5% 7.9 (6.45; 15.7) 9.36 (6.45; 15.7) 0.08 
FRC (L) 0.8 (0.48; 2.4) 1.1 (0.55; 2.8) 0.67 
Characteristics for patients excluded for further analysis due to not having >3 good quality 
MBW compared to included patients. Data are presented as median (range) or n (%). 
Definition of abbreviations: BMI = Body mass index, FEV1: forced expiratory volume in one 
second, LCI: Lung clearance index, FRC: Functional residual capacity. P-value refers to the 
comparison of characteristics of included and excluded patients.  
  











































Aspergillus colonization    
Not colonized 0.20 0.11; 0.29  
Newly acquired 0.28 0.17;0.39 0.02 
P. aeruginosa colonization    
Not colonized 0.19 0.01; 0.29  
Newly acquired 0.29 0.19;0.29 0.02 
H. influenzae  colonization    
Not colonized 0.24 0.14; 0.34  
Newly acquired 0.24 0.15; 0.34 0.17 
S.aureus colonization    
Not colonized 0.24 0.10. ; 0.39  
Newly acquired 0.26 0.18; 0.35 0.2 
Influence of newly acquired pathogen on the slope of LCI.  Results present the 
slope of LCI before  participants were colonized compared to the slope of LCI 
when a pathogen was acquired and the participant had repeated positive 
samples and was therefore considered intermittent or chronically colonized.  
* The slope coefficient is derived from the fully adjusted model (supplemental 
table E5) using age as the time variable and an interaction term for pathogen 
acquisition. 
A positive slope indicates a worsening LCI, whereas a negative slope indicates 
an improving LCI. Values in bold are statistically different from 0 at p <0.05 
significance level.  
 
Table E4: Covariates associated with changes in LCI derived from the full adjusted 
analysis 
 






Pancreatic insufficient    
No (N=5) 0.2 0.04; 0.35  
Yes (N=66) 0.24 0.16; 0.33 0.36 
Newborn screened     
No (N=63) 0.23 0.15; 0.32  
Yes (N=8) 0.15 -0.07; 0.36 0.18 
LCI at study entry    
<8 (N= 12) Age 7.7 (4.6 – 11.08) ‡ 0.18 0.02; 0.37  
> 8 (N=59) Age 8.7 (4 – 15.2) ‡ 0.25 0.16; 0.34 0.5 
Time of follow-up (years)  -0.17 -0.41; 0.08  
Hypertonic saline    
Yes (N=61) 0.27 0.18; 0.35  
No (N=10) 0.04 -0.19; 0.27 0.07 
Dornase Alfa    
Yes (N=12) 0.43 0.23; 0.64  
No (N=59) 0.23 0.12; 0.3 0.06 
Chronically inhaled antibiotics    
Yes (N=14) 0.41 0.24; 0.58  
No (N=57) 0.19 0.1; 0.28 0.02 
Visit specific covariates 
Coefficient  
(LCI units) † 
95% CI 
 
Any proinflammatory pathogen# 0.05 -0.18; 0.27 
 
1 proinflammatory pathogen# 0.03 -0.21; 0.27 
 
>1 proinflammatory pathogens# 0.09 -0.18; 0.37 
 
Acute P.aeruginosa  -0.16 -0.43; 0.11 
 
Acute Aspergillus  0.22 -0.10; 0.54 
 
Acute S.aureus 0.02 -0.20; 0.24 
 
Acute H.Influenzae 0.07 -0.19; 0.33 
 
Oral antibiotics 0.01 -0.1; 0.13  
Influence of clinical covariates on LCI course in the full adjusted analysis.  
Abbreviations: LCI u/year: LCI units per year, CI: Confidence interval, P.aeruginosa: 
Pseudomonas aeruginosa, S.aureus: Staphylococcus aureus, H.influenzae: 
Haemophilus influenzae 
* For time-invariant variables we report interaction terms with age to assess trends 
in LCI (slope coefficient of age) over the whole study period. Slope and main effects 
are derived from the fully adjusted model presented in table E5.  
†For visit-specific covariates, we report main effects to assess acute changes in LCI 
associated with the presence of the characteristic at a given time point.  
‡ The numbers refer to participants with an LCI below or above the upper limit of 
normal of 8 at study entry and corresponding the median age with its range.  
# Proinflammatory pathogens were considered S.aureus, P.aeruginosa, H.Influenzae, 
S.pneumoniae and Aspergillus and assessed as any proinflammatory pathogen and as 
additive effect.  
A positive coefficient indicates a worsening LCI (higher LCI), whereas a negative 
coefficient indicates an improving LCI (lower LCI). Values in bold are statistically 
different from 0 at p <0.05 significance level.  
  






Age 0.24 0.16; 0.33 
Sex    
Male baseline   
Female 0.44 -0.33; 1.2 
BMI z-score   -0.6 -0.84; -0.36 
P.aeruginosa   
Never colonized baseline  
Intermittend  0.68 -0.16; 1.52 
Chronic  1.63 0.5; 2.8 
Aspergillus   
Never colonized baseline  
Intermittend  0.71 -0.16; 1.6 
Chronic  1.6 0.16; 3.14 
CFRD   
absent baseline   
present 1.1 0.35; 1.73 
Acute Exacerbations 0.64 0.45; 0.82 
Severe exacerbations   
0 /year baseline  
1/year 0.14 -0.78; 1.05 
>1x/year 0.18 -0.7; 1.1 
No ABPA during study  baseline   
ABPA during study 0.71 0.15 – 1.26 
constant 5.68 4.6 ;  6.78 
 
  
Full adjusted model presented including all predefined covariates.  Definitions of 
abbreviations:  LCI u/year: Lung clearance index units per year; CI: Confidence interval, 
P.aeruginosa: Pseudomonas aeruginosa; ABPA: acute bronchopulmonary aspergillosis. 
*This table presents the covariates adjusted for in the final multilevel mixed effects 
model. Coefficient for age represents the slope for LCI increase per year of age. 
Coefficients for the other covariates represent the additional increase if the covariate 
is present that needs to be added to the constant plus the slope for age.  A positive 
coefficient indicates a worsening LCI (higher LCI), whereas a negative coefficient 
indicates an improving LCI (lower LCI). 

















 Females   Males   
       
Aspergillus 
colonization 
      
Never colonized 
(N=23) 
23 (52) 0.12 -0.02; 0.27 17 (63)  0.14 -0.02; 0.3 
Intermittent 17 (39) 0.33 0.19; 0.48 9 (33) 0.24 0.03; 0.46 
Chronic 4 (9) 0.43 0.16; 0.7 1 (4) 0.85 0.27; 1.4 
P.aeruginosa       
Never colonized 
(N=17) 
17 (38) 0.18 
 
-0.01; 0.36 14 (52) 0.19 0.001; 0.37 
Intermittent 21(48) 0.28 0.13; 0.42 8 (30) 0.11 -0.12; 0.34 
Chronic 6 (14) 0.28 0.02;  0.53 5 (18) 0.51 0.18; 0.84 
Severe exacerbations       
0 /year 20 (45) 0.06 -0.1; 0.22 16 (59) 0.17 -0.02; 0.35 
1/year 20 (45) 0.34 0.20; 0.47 11 (41) 0.28 0.05; 0.50 
>1x/year 4 (10) 0.45 0.20; 0.72 0   
No ABPA/study period 
(N=37) 
37 (84) 0.22 0.10; 0.33 25 (93) 0.14 0.002; 0.28 
ABPA / study period 7 (16) 0.34 0.20; 0.51 2 (7) 0.63 0.36; 0.90 
Prevalence and influence on LCI of risk factors for females and males. Definitions of 
abbreviations:  LCI u/year: Lung clearance index units per year;  CI: Confidence interval; 
Aspergillus: Aspergillus fumigatus; P.aeruginosa: Pseudomonas aeruginosa; ABPA: 
acute bronchopulmonary aspergillosis. 
Coefficients are derived from a multilevel mixed effects model adjusted for the main 
effects of final selected covariates (final model summarized in supplemental table E5). 
Covariates assessed are time-invariant and stable throughout the study period and 
analyses performed separately for females and males. 
* Slope represents the increase in LCI over time compared within the group 
characteristic.  The 95% CI represents the comparison to zero increase in LCI for each 
subgroup separately. A positive coefficient indicates a worsening LCI (higher LCI), 
whereas a negative coefficient indicates an improving LCI (lower LCI). 
Values in bold had a statistically significant interaction at a  significance level from 0 at 
p <0.05 for the comparison of the slopes within the group characteristic. 














95% CI p-value † 
Age           
3 - 5 years (N= 17) -0.16 -0.5; 0.21  -0.07 -0.49; 0.36  -0.06 -0.43; 0.31  
6 – 11 years (N= 42) -0.08 -0.15; -0.01  -0.08 -0.16; 0.01  -0.08 -0.14; 0.01  
12 – 18 years (N= 12) -0.11 -0.18; -0.04 0.8 -0.13 -0.21; -0.05 0.7 0.18 -0.4; 0.08 0.2 
Decrease in spirometry indices over time by age groups when adjusting for baseline characteristics (BMI and sex). Indices reported were FEV1 z-scores, 
FEF25-75 z-scores and FVC z-scores. Abbreviations: FEV1: Forced expiratory volume in one second ; FEF25-75: Mean forced expiratory flow between 25% and 75% 
of FVC; FVC: forced vital capacity, CI: Confidence interval.  
*  The slope coefficient is derived from the baseline model adjusted for sex and body mass index using age as the time variable and an interaction term for 
age group. 
† P- value is derived from the interaction within the group characteristic 
A negative coefficient indicates worsening spirometry, whereas a positive coefficient indicates improving spirometry. Values in bold are statistically different 
from 0 at p <0.05 significance level.  
 








Age     
3 - 5years (N= 17) -0.11 -0.5; 0.23  
6 – 11 years (N= 42) -0.08 -0.15; -0.01  
12 – 18 years (N= 12) -0.08 -0.15; -0.02 0.2 
Sex    
Males (N=27) -0.04 -0.12; 0.03  
Females (N=44) -0.1 -0.16;-0.05 0.19 
    
Aspergillus colonization      
Never colonized (N=40) -0.06 -0.12; 0.01  
Intermittent (N=26) -0.11 -0.18; -0.04  
Chronic (N=5) -0.09 -0.23; 0.05 0.2 
    
P. aeruginosa colonization    
Never colonized (N=31) -0.06 -0.13;  0.01  
Intermittent(N=29) -0.08 -0.15; -0.02  
Chronic (N=11) -0.13 -0.24; -0.03 1.0 
    
Severe exacerbations (N/year)    
0 /year (N=36) -0.04 -0.1 ; 0.02  
1/year (N=31) 
 
-0.1 -0.16; -0.04  
>1x/year (N=4) -0.23 -0.4; -0.07 0.06 
    
No ABPA /study period (N=62) -0.08 -0.13; -0.04  
ABPA / study period (N=9) -0.08 -0.16; 0.01 0.2 
    
Influence of clinical covariates on spirometry in the fully adjusted analysis. Definitions of 
abbreviations:  FEV1: Forced expiratory volume in one second; CI: Confidence interval; 
Aspergillus: Aspergillus fumigatus;  P.aeruginosa: Pseudomonas aeruginosa; I.v.: intravenous;  
ABPA: acute bronchopulmonary aspergillosis. 
Covariates assessed are time-invariant and were considered over the entire study period. The 
slope coefficients are derived from a multilevel mixed effects model adjusted for the main 
effects of final selected covariates (final model summarized in supplemental table E5). 
* Slope represents the increase in FEV1 z-scores over time compared within the group 
characteristic.  The 95% CI represents the comparison to zero increase in  FEV1 z-scores for 
each subgroup separately. A negative coefficient indicates a decrease in FEV1 z-scores  (lower 
lung function), whereas a positive coefficient indicates an increased FEV1 z-score (better lung 
function).  
Values in bold show a statistically significant difference from 0 at p <0.05 significance level for 
the comparison of the slopes within the group characteristic.  










95% CI p-value for 
interaction 
Age        
3 - 5.9 years (N= 17) -0.04 -0.44; 0.36  -0.02 -0.40; 0.34  
6 – 11.9 years (N= 42) -0.06 -0.14; 0.01  -0.08 -0.15; -0.02  
12 – 18 years (N= 12) -0.09 -0.16; -0.01 0.05 0.03 -0.03; 0.09 0.1 
Sex       
Males (N=27) -0.02 -0.1; 0.05  -0.01 -0.07; 0.06  
Females (N=44) -0.10 -0.15; -0.04 0.1 -0.05 -0.1; 0.01 0.3 
Aspergillus colonization         
Never colonized (N=40) -0.05 -0.11; 0.01  -0.02 -0.08; 0.03  
Intermittent (N=26) -0.11 -0.18; -0.15  -0.02 -0.08; 0.04  
Chronic (N=5) 0.01 -0.13; 0.05 0.02 -0.11 -0.24; 0.02 0.2 
P. aeruginosa colonization       
Never colonized (N=31) -0.05 -0.12;  0.03  -0.04 -0.1; 0.03  
Intermittent(N=29) -0.06 -0.13; -0.01  -0.03 -0.09; 0.03  
Chronic (N=11) -0.11 -0.22; -0.03 1.0 -0.03 -0.13; 0.07 0.6 
Severe exacerbations (N/year)       
0 /year (N=36) -0.05 -0.1; 0.01  0.01 -0.05; 0.07  
1/year (N=31) 
-0.06 -0.13; 0.01  -0.05 -0.11; 0.01  
>1x/year (N=4) 
-0.16 -0.3; 0.01 1.0 -0.16 -0.31; -0.01 0.04 
No ABPA /study period (N=62) -0.06 -0.13 ; -0.01  -0.04 -0.09; 0.01  
ABPA / study period (N=9) -0.09 -0.18; -0.01 0.02 0.01 -0.07; 0.08 0.15 
Influence of clinical covariates on spirometry in the fully adjusted analysis. Definitions of abbreviations: FEF25-75: Mean forced expiratory 
flow between 25% and 75% of FVC; FVC: forced vital capacity, CI: Confidence interval; Aspergillus: Aspergillus fumigatus;  P.aeruginosa: 
Pseudomonas aeruginosa; I.v.: intravenous;  ABPA: acute bronchopulmonary aspergillosis. 
Covariates assessed are time-invariant and stable throughout the study period. The slope coefficients are derived from a multilevel mixed 
effects model adjusted for the main effects of final selected covariates (final model summarized in supplemental table E5). 
* Slope represents the increase in FEF25-75 / FVC z-scores over time compared within the group characteristic.  The 95% CI represents the 
comparison to zero increase in  FEF25-75 / FVC z-scores for each subgroup separately. A negative coefficient indicates a decrease in FEF25-75 / 
FVC z-scores  (lower lung function), whereas a positive coefficient indicates an increased FEF25-75 / FVC z-score (better lung function).  




Table E10: Covariates associated with acute changes in FEV1 z-scores, FEF25-75 z-scores, and FVC z-scores 
 
 FEV1 z-scores 95% CI FEF25-75 z-scores 95% CI FVC z-scores 95% CI 
Acute Exacerbations (N = 586/907) -0.05 -0.56; -0.37 -0.42 -0.53;  -0.31 -0.38 -0.48;  -0.28 
CF-related diabetes (N=84/907) 0.17 -0.17; 0.52 -0.38 -0.76;  0.01 0.44 -0.09;  0.79 
BMI z-score  0.44 0.32; 0.56 0.39 0.25; 0.53 0.38 0.26; 0.50 
Acute effects of clinical covariates on spirometry in the fully adjusted analysis. Definitions of abbreviations:  FEV1: Forced expiratory volume 
in one second; FEF25-75: Mean forced expiratory flow between 25% and 75% of FVC; FVC: forced vital capacity, CI: Confidence interval; CF: 
cystic fibrosis; BMI: Body mass index. 
Coefficients represent the increase in spirometry z-scores at a given timepoint compared to those without the characteristic (95% confidence 
interval) and are derived from a multilevel mixed effects model adjusted for the main effects of final selected covariates (final model 
summarized in supplemental table E5).  A negative coefficient indicates a decrease in spirometry z-scores  (lower lung function), whereas a 






















Figure E1: FEV1 z-scores decrease over time without adjustments. The decrease in FEV1 z-scores is shown over age and found, on average, to be -0.09 FEV1 z-
score/year (95% CI -0.14 - -0.05). During preschool age (3 – 5 years), the increase was found to be -0.16 FEV1 z-score/year (95% CI -0.5; 0.21); during school 
age (6 – 11 years) -0.08 FEV1 z-score/year (95% CI -0.15; -0.01); during adolescence (12-18 years) -0.11 FEV1 z-score/year (95% CI -0.18; -0.04), p-value for 
interaction 0.8). On the y-axis,  FEV1 z-scores are given. Line represents mean FEV1 z-score across all subjects with available data at a given age. Shaded areas 
represent point-wise upper and lower 95% confidence intervals. Dotted line represents the lower limit of normal of -1.64 z-scores. Abbreviations: FEV1: 

























Figure E2: FEV1 z-scores decrease over time with adjustments for risk factors. The decrease in FEV1 z-scores after adjusting for risk factors (full model 
presented in table E5) is shown over age and found, on average, to be  -0.08 FEV1 z-scores/year (95%CI -0.13 - -0.04). During preschool age (3 - 5 years), the 
increase was found to be -0.11 FEV1 z-score/year (95% CI -0.5; 0.23); during school age (6 – 11 years) -0.08 FEV1 z-score/year (95% CI -0.15; -0.01); during 
adolescence (12-18 years) -0.08 FEV1 z-score/year (95% CI -0.15; -0.02), p-value for interaction 0.2). On the y-axis,  FEV1 z-scores are given. Line represents 
mean FEV1 z-score across all subjects with available data at a given age. Shaded areas represent point-wise upper and lower 95% confidence intervals. Dotted 
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